New tRNA Mechanism Identified as Driver of Treatment Resistance in Advanced Prostate Cancer
A multi-institutional team led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer.
- Researchers discovered that a transfer RNA named tRNAArg (UCU)-1 acts as a molecular switch in advanced prostate cancer, driving therapy resistance.
- As tumors transition to a therapy-resistant state, tRNAArg (UCU)-1 levels consistently drop, reducing the production of SMARCC2 and disrupting normal cell identity.
- Restoring tRNAArg (UCU)-1 or SMARCC2 successfully rescued androgen receptor activity, offering a potential path for RNA-targeted therapeutics to re-sensitize resistant tumors.
Tumors Adapt Through Lineage Plasticity to Resist Therapy
Prostate cancer stands as the second-leading cause of cancer death among men in the United States. Initial tumor growth frequently relies on androgen receptor signaling. Many patients initially respond well to androgen deprivation therapies and androgen receptor pathway inhibitors like enzalutamide, apalutamide, and darolutamide. However, tumors frequently adapt over time through lineage plasticity. During this transition, cancer cells shed their dependence on androgen signaling and acquire features of neuroendocrine prostate cancer, an aggressive form that resists standard therapy.
The molecular cues driving this transformation remained poorly understood until the study published in Nature shed light on the process. Using high-resolution RNA sequencing on samples from patients, animal models, and cells, the research team discovered that tRNAArg (UCU)-1 is consistently depleted as tumors shift from a therapy-responsive state to a resistant one.
Historically, scientists viewed tRNAs merely as routine housekeeping components acting as fixed carrier molecules to translate the genetic code during protein synthesis. Conversely, cellular fate is actually regulated by dynamically adjusted tRNA concentrations, where diminished amounts of tRNAArg (UCU)-1 function as a biological toggle enabling prostate cancer cells to evade therapy and transform into a more virulent malignancy.
Restoring Treatment Sensitivity Through RNA Modulation
To understand the mechanics of this switch, the researchers traced the pathway linking tRNAArg (UCU)-1 to the cellular machinery governing prostate cell identity. When the team experimentally reduced levels of tRNAArg (UCU)-1 in prostate cancer cells, the cells rapidly displayed lower levels of androgen receptor, which is a key driver that many prostate cancer treatments are designed to block. Further investigation revealed that two proteins, TARDBP and ZSCAN29, help keep this specific tRNA active.
tRNAArg (UCU)-1 helps regulate the production of SMARCC2, a critical component of the cellular machinery that organizes DNA and maintains the treatment-sensitive state of prostate cells. When tRNAArg (UCU)-1 levels fall, SMARCC2 production drops. This disruption alters cell identity and accelerates the conversion into a therapy-resistant form. When the researchers restored tRNAArg (UCU)-1 or SMARCC2, they successfully rescued androgen receptor activity and made the resistant cells responsive to treatment again.
Targeting RNA Processes Could Re-Sensitize Resistant Tumors
Current treatment options for patients with treatment-resistant neuroendocrine prostate cancer are largely restricted to platinum-based chemotherapies, which provide only modest survival benefits. The finding that tRNA modulation can reverse lineage switching suggests that RNA-targeted therapeutics—such as synthetic tRNA mimics or small molecules designed to enhance tRNAArg (UCU)-1 production—could re-sensitize difficult tumors to existing androgen receptor-targeted drugs.
Unlike permanent DNA mutations, RNA-regulated processes are reversible. This opens up unexplored therapeutic options centered on modulating RNA dosage and tRNA to overcome drug resistance.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Related reading
- Effects of Multisensory Stimulation on Preterm Infant Development
- Italy Awaits Pancreatic Cancer Drug: When Will Daraxonrasib Arrive?
- Estrogen Patch Labels Now Box Only Uterine Cancer; Clot Warnings Remain (daybreakwire.com)
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)